Eat Your Broccoli: Oxidative Stress, NRF2, and Sulforaphane in Chronic Kidney Disease.
Scott E LiebmanThu H LePublished in: Nutrients (2021)
The mainstay of therapy for chronic kidney disease is control of blood pressure and proteinuria through the use of angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) that were introduced more than 20 years ago. Yet, many chronic kidney disease (CKD) patients still progress to end-stage kidney disease-the ultimate in failed prevention. While increased oxidative stress is a major molecular underpinning of CKD progression, no treatment modality specifically targeting oxidative stress has been established clinically. Here, we review the influence of oxidative stress in CKD, and discuss regarding the role of the Nrf2 pathway in kidney disease from studies using genetic and pharmacologic approaches in animal models and clinical trials. We will then focus on the promising therapeutic potential of sulforaphane, an isothiocyanate derived from cruciferous vegetables that has garnered significant attention over the past decade for its potent Nrf2-activating effect, and implications for precision medicine.
Keyphrases
- oxidative stress
- chronic kidney disease
- end stage renal disease
- angiotensin converting enzyme
- angiotensin ii
- diabetic rats
- blood pressure
- dna damage
- ischemia reperfusion injury
- clinical trial
- induced apoptosis
- peritoneal dialysis
- signaling pathway
- ejection fraction
- risk assessment
- cancer therapy
- working memory
- study protocol
- prognostic factors
- health risk assessment
- insulin resistance
- human health
- blood glucose
- metabolic syndrome
- single molecule
- phase ii
- placebo controlled